Alexander Hardy

President, Chief Executive Officer & Director, BIOMARIN PHARMACEUTICAL INC

Search every verified Alexander Hardy interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. In a March 2026 podcast appearance, Alexander Hardy, President and CEO of BioMarin, discussed his career trajectory across small molecules, biologics, oncology, and rare diseases, and reflected on how his work in access and patient services shaped his leadership approach. He addressed the policy environment in Washington, including the Inflation Reduction Act and other pricing reforms, and their influence on long-term innovation and investment decisions. Hardy also noted a shift in the industry toward generating meaningful post-approval data for rare disease treatments, describing regulatory approval as a starting point rather than a finish line. Hardy commented on challenges facing rare disease patients, stating that managed care plans are increasingly applying utilization management tools such as prior authorizations, which he said create navigation burdens for caregivers and families. He expressed support for bipartisan efforts to reform pharmacy benefit managers and for pending legislation aimed at restricting prior authorization requirements in rare diseases, arguing that such measures would help the market function more efficiently and benefit patients.